NCT03682211View on ClinicalTrials.gov

Intranasal Fentanyl Versus Intravenous Morphine in the Treatment of Severe Painful Sickle Cell Crises in Children

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 12, 2012

Primary Completion Date

November 14, 2013

Study Completion Date

November 14, 2013

Conditions
PainSickle Cell Disease
Interventions
DRUG

Fentanyl Citrate

50 μg/ml fentanyl citrate (Sublimaze, Janssen Cilag, Ltd, Marketing Authorisation No. PA 0748/044/001) administered intranasally using the MAD Nasal Intranasal Mucosal Atomiser Device

DRUG

Morphine sulphate

10 mg/ml Morphine sulphate BP (Antigen Pharmaceuticals, Marketing Authorisation No.PA 73/20/1) administered intravenously.

Trial Locations (1)

Unknown

Our Lady's Children's Hospital, Crumlin, Dublin

All Listed Sponsors
collaborator

National Children's Research Centre

UNKNOWN

collaborator

Our Lady's Children's Hospital, Crumlin

UNKNOWN

lead

University College Dublin

OTHER

NCT03682211 - Intranasal Fentanyl Versus Intravenous Morphine in the Treatment of Severe Painful Sickle Cell Crises in Children | Biotech Hunter | Biotech Hunter